Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

bioAffinity Technologies (BIAF) Accumulated Expenses (2022 - 2025)

bioAffinity Technologies (BIAF) has disclosed Accumulated Expenses for 4 consecutive years, with $984547.0 as the latest value for Q3 2025.

  • On a quarterly basis, Accumulated Expenses rose 49.33% to $984547.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $984547.0, a 49.33% increase, with the full-year FY2024 number at $1.1 million, up 26.0% from a year prior.
  • Accumulated Expenses was $984547.0 for Q3 2025 at bioAffinity Technologies, up from $776065.0 in the prior quarter.
  • In the past five years, Accumulated Expenses ranged from a high of $1.6 million in Q3 2022 to a low of $276519.0 in Q2 2023.
  • A 4-year average of $821918.2 and a median of $857037.0 in 2023 define the central range for Accumulated Expenses.
  • Peak YoY movement for Accumulated Expenses: tumbled 59.76% in 2023, then surged 250.46% in 2024.
  • bioAffinity Technologies' Accumulated Expenses stood at $541894.0 in 2022, then skyrocketed by 58.16% to $857037.0 in 2023, then increased by 26.0% to $1.1 million in 2024, then dropped by 8.82% to $984547.0 in 2025.
  • Per Business Quant, the three most recent readings for BIAF's Accumulated Expenses are $984547.0 (Q3 2025), $776065.0 (Q2 2025), and $932208.0 (Q1 2025).